Methylphenidate in the treatment of attention-deficit/hyperactivity disorder: Are we doing a good clinical practice?;Metilfenidato en el tratamiento del trastorno por déficit de atención e hiperactividad: ¿Realizamos una práctica clínica adecuada?

Revista de Neurologia

Volumn 43, Issue 12, 2006, Pages 705-714

  González De Dios, Javier ^a,d   Cardo E ^b,c   Servera, M ^c  

^a HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^b HOSPITAL SON LLÀTZER   (Spain)

^c UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^d NONE   (Spain)

Author keywords

Attention deficit hyperactivity disorder; Bibliographic databases; Critical appraisal topics; Evidence based medicine; Methylphenidate

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CLONIDINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; METHYLPHENIDATE; MODAFINIL; PEMOLINE; PEMOLINE MAGNESIUM; PSYCHOSTIMULANT AGENT; QUEMEN; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; ZYNTABAC; PROPYLAMINE;

ALGORITHM; ATTENTION DEFICIT DISORDER; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COCHRANE LIBRARY; COST BENEFIT ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GOOD CLINICAL PRACTICE; HUMAN; LONG TERM CARE; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDLINE; METHODOLOGY; OUTCOME ASSESSMENT; PUBLICATION; REVIEW; SUSTAINED DRUG RELEASE; SYSTEMATIC REVIEW; TIMED DRUG RELEASE; TREATMENT DURATION; ADOLESCENT; BIBLIOGRAPHIC DATABASE; BIBLIOMETRICS; CHILD; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; HEALTH CARE QUALITY; INFANT; MALE; META ANALYSIS; PRESCHOOL CHILD; PROFESSIONAL PRACTICE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIBLIOMETRICS; CHILD; CHILD, PRESCHOOL; DATABASES, BIBLIOGRAPHIC; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INFANT; MALE; META-ANALYSIS; METHYLPHENIDATE; PROFESSIONAL PRACTICE; PROPYLAMINES; QUALITY OF HEALTH CARE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 35348873915     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4312.2005826     Document Type: Review

References (134)

1. Still GF. Some abnormal psychological conditions in children. Lancet 1902; 1: 1008-12.
2. a entrega): 3-25.
3. Cardo-Jalón E, Servera-Barceló M. Trastorno por déficit de atención con hiperactividad. Una visión global. An Pediatr (Barc) 2003; 59: 225-8.
4. Peña JA, Montiel Nava C. Trastorno por déficit de atención/hiperactividad: ¿mito o realidad? Rev Neurol 2003; 36: 173-9.
5. González de Dios J. Búsqueda de información en pediatría basada en la evidencia (II): fuentes de información secundarias y primarias. Rev Esp Pediatr 2003; 59: 259-73.
6. Jovell AJ, Navarro Rubio MD. Evaluación de la evidencia científica. Med Clin (Barc) 1995; 105: 740-3.
7. Donnelly M, Haby MM, Carter R, Andrews G, Vos T. Cost-effectiveness of desamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder. Austr NZ J Psychiatry 2004; 38: 592-601. NSH EED abstract 20021631. URL: http://nhscrd.york.ac.uk/online/nhseed/20041130.htm. Fecha última consulta: 18.11.2005.
8. Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 2001; 165: 1475-88.
9. Evidence-Based Mental Health 2002; 5: 50. Fecha última consulta: 18.11.2005.
10. Pelhman WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, et al. Once-a-day concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001; 107: 105.
11. Evidence-Based Mental Health 2002; 5: 20. Fecha última consulta: 18.11.2005.
12. Purdie N, Hattie J, Carroll A. A review of the research on interventions for attention deficit hyperactivity disorder: what works best. Rev Edu Res 2002; 72: 61-99. DARE abstract 20026678. URL: http://nhscrd.york.ac.uk/online/dare/ 20026678.htm. Fecha última consulta: 18.11.2005.
13. Gilmore A, Milen R. Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepidemiol Drug Saf 2001; 10: 85-94. NSH EED abstract 20011358. URL: http://nhscrd.york.ac.uk/online/nhseed/20011358. htm. Fecha última consulta: 18.11.2005.
14. Gilmore A, Milen R. Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepidemiol Drug Saf 2001; 10: 85-94. DARE 20011693. URL: http://nhscrd.york.ac.uk/online/dare/2001693.htm. Fecha última consulta: 18.11.2005.
15. Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 2001; 165: 1475-88. DARE 20028090. URL: http://nhscrd.york.ac.uk/online/dare/20028090.htm. Fecha última consulta: 18.11.2005.
16. Law SF, Schachar RJ. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry 1999; 38: 944-51.
17. Evidence-Based Mental Health 2000; 3: 31. Fecha última consulta: 18.11.2005.
18. Jadad AR, Boyle M, Cunningham C, Kim M, Schachar R. Treatment of attention-deficit/hyperactivity disorder. Rockville, MD: Agency for Health Care Policy and Research (Evid Rep Technol Assess, 11); 1999. p. 341.
19. Evidence-Based Mental Health 2000; 5: 179. Fecha última consulta: 18.11.2005.
20. Smith BH, Waschbusch DA, Willoughby MT, Evans S. The efficacy, safety, and practically of treatments for adolescents with attention-deficit/ hyperactivity disorder (ADHD). Clin Child Fam Psychol Rev 2000; 3: 243-67. DARE 20013548. URL: http://agatha.york.ac.uk/online/dare/20013548.htm. Fecha última consulta: 18.11.2005.
21. Klassen A, Millar A, Raina P, Lee SK, Olsen L. Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies. Can J Psychiatry 1999; 44: 1007-16. DARE 20000242. URL: http://agatha.york.ac.uk/online/dare/20000242.htm. Fecha última consulta: 18.11.2005.
22. Jadad AR, Boyle M, Cunningham C, Kim M, Schachar R. Treatment of attention-deficit/hyperactivity disorder. Rockville, MD: Agency for Health Care Policy and Research (Evid Rep Technol Assess, 11); 1999. p. 341. DARE 20008341. URL: http://agatha.york.ac.uk/online/dare/20008341.htm. Fecha última consulta: 18.11.2005.
23. Jadad AR, Boyle M, Cunningham C, Kim M, Schachar R. Treatment of attention-deficit/hyperactivity disorder. Rockville, MD: Agency for Health Care Policy and Research (Evid Rep Technol Assess, 11); 1999. p. 341. HTA 20020340. URL: http://agatha.york.ac.uk/online/hta/20020340.htm. Fecha última consulta: 18.11.2005.
24. Shukla VK, Otten N. Assessment of attention deficit/hyperactivity disorder therapy: a canadian perspective. Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA); 1999. HTA 998360. URL: http://agatha.york.ac.uk/online/hta/998360.htm. Fecha última consulta: 18.11.2005.
25. Diamond IR, Tannock R, Schachar RJ. Response to methylphenidate in children with ADHD and comorbid anxiety. J Am Acad Chil Adolesc Psychiatry 1999; 38: 402-9.
26. Evidence-Based Mental Health 1999. Vol. 108. Fecha última consulta: 18.11.2005.
27. Gillberg C, Melander H, Von Knorring AL, Janols LO, Themlund G, Hagglof B, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54: 857-64.
28. Evidence-Based Mental Health 1998. Vol. 86. Fecha última consulta: 18.11.2005.
29. Klein RG, Abikoff H, Klass E, Ganeles D, Seese LM, Pollack S. Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry 1997; 54: 1073-80.
30. Evidence-Based Mental Health 1998. Vol. 87. Fecha última consulta: 18.11.2005.
31. Gilmore A, Best L, Milne R. Methylphenidate in children with hyperactivity. Southampton: Wessex Institute for Health Research and Development (WIHRD), 1998. HTA 988896. URL: http://agatha.york.ac.uk/online/hta/988896.htm. Fecha última consulta: 18.11.2005.
32. Loisier BJ, McGrath PJ, Klein RM. Error patterns on the continuous performance test in non-medicated and medicated simples of children with and without ADHD: a meta-analytic review. J Child Psychol Psychiatry 1996; 37: 971-87. DARE 973267. URL: http://agatha.york.ac.uk/online/dare/973267.htm. Fecha última consulta: 18.11.2005.
33. Institute for Clinical Systems Improvement (ICSI). Diagnosis and management of attention deficit hyperactivity disorder in primary care for school age children and adolescents. Bloomington, MN: Institute for Clinical Systems Improvement (ICSI); 2005. National Guideline Clearinghouse NGC: 004071. URL: http://www.guideline.gov/summary/summary.aspx?doc_id=6498&nbr=004071. Fecha última consulta: 18.11.2005.
34. Cincinnati Children's Hospital Medical Center. Evidence based clinical practice guideline for outpatient evaluation and management of attention deficit/hyperactivity disorder. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2004. National Guideline Clearinghouse NGC: 003647. URL: http://www.guideline.gov/summary/summary.aspx?doc_id=5334&nbr=003647. Fecha última consulta: 18.11.2005.
35. Prodigy guidance-attention deficit disorder-methylphenidate. NICE guidance. URL: http://www.prodigy.nhs.uk/guidance.asp?gt=ADHD%20- %20methylphenidate%20(NICE). Fecha última consulta: 18.11.2005.
36. Canadian Paediatric Society. The use of alternative therapies in treating children with attention deficit hyperactivity disorder. Paediatr Child Health 2002; 7: 710-8. CMA Infobase. URL: http://www.cps.ca/english/statements/PP/pp02- 03.pdf. Fecha última consulta: 18.11.2005.
37. Canadian Paediatric Society. The use of stimulant medication in the treatment of attention deficit hyperactivity disorder. Paeditr Child Health 2002; 7: 693-6. CMA Infobase. URL: http://www. cps.ca/english/statements/PP/ pp02-02.pdf. Fecha última consulta: 18.11.2005.
38. New Zealand Guidelines for the assessment and treatment of attention-deficit/hyperactivity disorder. New Zealand Guidelines Group. URL: http://www.nzgg.org.nz/guidelines/0069/ADHDGuidelines.pdf. Fecha última consulta: 18.11.2005.
39. American Academy of Pediatrics. Clinical practice guidelines: treatment of the school-age child with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 1033-44. National Guideline Clearinghouse NGC: 002298. URL: http://www.guideline.gov/summary/summary.aspx?doc_id=3072&nbr=002298. Fecha última consulta: 18.11.2005.
40. What is the current evidence for monitoring of Ritalin and what should we be monitoring and how often? ATTRACT, 2004. URL: http://www.attract.wales.nhs. uk/question_answers.cfm?question_id=1696. Fecha última consulta: 18.11.2005.
41. A male patient of 16 has been on Ritalin for ADHD for 14 years. What are the risks of continuining this treatment, and if he stops how should the drug be withdrawn? ATTRACT, 2003. URL: http://www.attract.wales.nhs.uk/ question_answers.cfm?question_id=1383. Fecha última consulta: 18.11.2005.
42. Bjornstad G, Montgomery P. Terapia familiar para el trastorno por déficit de atención o el trastorno por déficit de atención e hiperactividad en niños y adolescentes (revisión Cochrane traducida). In La Biblioteca Cochrane Plus, número 3. Oxford: Update Sotware Ltd; 2005.
43. (Traducido de The Cochrane Library, issue 3. Chichester: John Wiley & Sons, Ltd; 2005.) URL: http://www.update-sofware.com. Fecha última consulta: 18.11.2005.
44. Methylphenidate, atomoxetine and desamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents including review of existing NICE guidance number 13 (Guidance on the use of methylphenidate [Rytalin, Equasym] for attention deficit/hyperactivity disorder -ADHD- in childhood)-systematic review (project). HTA 20030774. URL: http://nhscrd.york. ac.uk/online/hta/20030774.htm. Fecha última consulta: 18.11.2005.
45. National Institute for Clinical Excellence. Methylphenidate (Ritalin, Equasym) for attention deficit/ hyperactivity disorder (ADHD) in childhood. London: National Institute for Clinical Excellence (NICE); 2000. p. 13. HTA 20001776. URL: http://nhscrd.york.ac.uk/online/hta/20001776.htm. Fecha última consulta: 18.11.2005.
46. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41 (Suppl 2): S26-49. National Guideline Clearinghouse NGC: 002244. URL: http://www.guideline.gov/summary/summary.aspx?doc_id=3018&nbr=002244. Fecha última consulta: 18.11.2005.
47. Faraone SV, Biederman J, Roe C. Comparative efficacy of adderall and methylphenidate in attention-deficit/ hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol 2002; 22: 468-73.
48. Pelham WE Jr, Manos MJ, Exxell CE, Tresco KE, Gnagy EM, Hoffman MT, et al. A dose-ranging study of a methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005; 44: 522-9.
49. Stein MA, Sarampote CS, Walkman ID, Robb AS, Conlon C, Peral PL, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003; 112: 404-13.
50. Szobot CM, Ketzer C, Parente MA, Biederman J, Rohde LA. The acute effect of methylphenidate in Brazilian male children and adolescents with ADHD: a randomized clinical trial. J Atten Disord 2004; 8: 37-43.
51. Sonuga-Barke EJ, Swanson JM, Coghill D, DeCory HH, Hatch SJ. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 2004; 4: 28.
52. Dopfner M, Gerber WD, Banaschewski T, Breuer D, Freisleder FJ, Gerber-von Muller G, et al. Comparative effect of once-a-day extended-release methylphenidate, two-times-daily immediate-release methyl phenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry 2004; 13 (Suppl 1): 93-101.
53. Hechtman L, Abikoff H, Klein RG, Greenfield B, Etcovitch J, Cousins L, et al. Children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment: impact on parental practices. J Am Acad Child Adolesc Psychiatry 2004; 43: 830-8.
54. Abikoff H, Hechtman L, Klein RG, Gallagher R, Fleiss K, Etcovitch J, et al. Social functioning in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 2004; 43: 820-9.
55. Hechtman L, Abikoff H, Klein RG, Weiss G, Respitz C, Kouri J, et al. Academic achievement and emocional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 2004; 43: 812-9.
56. Abikoff H, Hechtman L, Klein RG, Weiss G, Fleiss K, Etcovitch J, et al. Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 2004; 43: 802-11.
57. Klein RG, Abikoff H, Hechtman L, Weiss G. Design and rationale of controlled study of long-term methylphenidate and multimodal psychosocial treatment in children with ADHD. J Am Acad Child Adolesc Psychiatry 2004; 43: 792-801.
58. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 2004; 113: 206-16.
59. Biederman J, Quinn D, Weiss, Markabi S, Weidenman M, Edson K, et al. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs 2003; 5: 833-41.
60. Lopez F, Silva R, Pestreich L, Muniz R. Comparative efficacy of two daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatr Drugs 2003; 5: 545-55.
61. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003; 60: 204-11.
62. Greenhill LL, Findling RL, Swanson JM, and the MPH MR ADHD Study Group. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002; 109: 39.
63. Wolraich ML, Greenhill LL, Pelma W, Swanson J, Wilens T, Palumbo D, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 883-92.
64. García Pérez A, Expósito Torrejón J, Martínez Granero MA, Quintana Rioja A, Bonet Serra A. Semiología clínica del trastorno por déficit de atención con hiperactividad en función de la edad y eficacia de los tratamientos en las distintas edades. Rev Neurol 2005; 41: 517-24.
65. Mulas F, Mattos L, Hernández Muela S, Gandía R. Actualización terapéutica en el trastorno por déficit de atención e hiperactividad: metilfenidato de liberación prolongada. Rev Neurol 2005; 40 (Supl 1): S49-55.
66. Cardo E, Servera M. Tratamiento del trastorno de déficit de atención e hiperactividad. An Pediatr Contin 2005; 3: 173-6.
67. San Sebastián Cabasés J, Quintero Gutiérrez del Alamo FJ. Tratamiento multimodal del trastorno por déficit de atención con hiperactividad (TDAH). Rev Esp Pediatr 2005; 61: 503-14.
68. Artiga-Pallarés J. Nuevas opciones terapéuticas en el trastorno por déficit de atención e hiperactividad. Rev Neurol 2004; 38 (Supl 1): S117-23.
69. Valdizán-Usón JR. Correlación electroclínica diagnóstica y terapéutica con metilfenidato de acción inmediata en TDAH. Rev Esp Pediatr 2004; 60: 181-7.
70. Valdizán JR. Evaluación diagnóstica y bases terapéuticas del metilfenidato de liberación inmediata en el trastorno por déficit de atención con hiperactividad. Rev Neurol 2004; 38: 501-6.
71. Domínguez-Ortega L, Pérez-Peñate G. Diagnóstico y tratamiento farmacológico del trastorno por déficit de atención e hiperactividad. Med Clin (Barc) 2003; 121: 437-8.
72. Papazian O, Alfonso I, García V. Efecto de la discontinuación del metilfenidato al comienzo de la adolescencia sobre el trastorno por déficit de atención en la edad adulta. Rev Neurol 2002; 35: 24-8.
73. Montiel-Nava C, Peña JA, Espina-Marines G, Ferrer-Hernández ME, López-Rubio A, Puertas-Sánchez S, et al. Estudio piloto de metilfenidato y entrenamiento a padres en el tratamiento de niños con trastorno por déficit de atención-hiperactividad. Rev Neurol 2002; 35: 201-5.
74. Mulas F, Roselló B, Morant A, Hernández S, Pitarch I. Efectos de los psicoestimulantes en el desempeño cognitivo y conductual de los niños con déficit de atención e hiperactividad subtipo combinado. Rev Neurol 2002; 35: 17-24.
75. Gracia R, Sánchez F, Herreros O. Nuevas perspectivas farmacológicas en el trastorno por déficit de atención/ hiperactividad. Rev Psiquiatr Inf Juv 2002; 19: 132-42.
76. Tuchman RF. Tratamiento del trastorno por déficit de atención con hiperactividad. Rev Neurol 2001; 33: 210-5.
77. American Academy of Pediatrics. Clinical practice guidelines: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 2000; 105: 1158-70.
78. Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, et al. European clinical guidelines for hyperkinetic disorder-first upgrade. Eur Child Adolesc Psychiatry 2004; 13 (Suppl 1): 17-30.
79. Dulcan MK, Benson RS. AACAP Oficial Action. Summary of the practice parameters for the assessment and treatment of children, adolescents, and adults with ADHD. J Am Acad Child Adolesc Psychiatry 1997; 36: 1311-7.
80. NIH Consensus Development Conference. Diagnosis and treatment of attention-deficit/hyperactivity disorder. Washington, DC: National Institutes of Health Medical Education; 1998.
81. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998; 279: 1100-7.
82. Hill P, Taylor E. An auditable protocol for treating attention-deficit/ hyperactivity disorder. Arch Dis Child 2001; 84: 404-9.
83. Barkley R. Internatinal consensus statement on ADHD. Clin Child Fam Psychol Rev 2002; 5: 89-111.
84. Kutchner S, Aman M, Brooks SJ, Buitelaar J, Van Daalen E, Fegert J, et al. International consensus statement on attention deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 2004; 14: 11-28.
85. Foy JM, Earls MF. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder. Pediatrics 2005; 115: 97-104.
86. Miller A, Lee SK, Raina P, Klassen A, Zupancic J, Olsen L. A review of therapies for attention-deficit/ hyperactivity disorder. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment; 1998.
87. Green M, Wong M, Atkins D, Taylor J, Feinlieb M. Diagnosis of attention-deficit/hyperactivity disorder (Technical Review 3). Rockville, MD: US Department of Health and Human Services, Agency for Health Care Policy and Research; 1999.
88. Lord J, Paisley S. The clinical effectiveness and cost-affectiveness of methylphenidate for hyperactivity in childhood. London: National Institute for Clinical Excellence; 2000.
89. Jadad AR, Booker L, Gauld M, Kakuma R, Boyle M, Cunningham CE, et al. The treatment of attention-deficit hyperactivity disorder: an annotated bibliography and critical appraisal of published systematic review and metaanalyses. Can J Psychiatry 1999; 44: 1025-35.
90. Klassen A, Miller A, Raina P, Lee SK, Olsen L. Attention-deficit/ hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies. Can J Psychiatry 1999; 44: 1007-16.
91. Liu YH, Stein MT. Attention-deficit/hyperactivity disorder: evidence-based diagnosis and management for primary care clinicians. Minerva Pediatr 2004; 56: 567-83.
92. Guevara J, Stein MT. Evidence based management of attention deficit hyperactivity disorder. BMJ 2001; 323: 1232-5.
93. Brown RT, Amler RW, Freeman WS, Perrin JM, Stein MT, Feldman HM, et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics 2005; 115: 749-57
94. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41 (Suppl 2): S26-49
95. Soutullo C. Diagnóstico y tratamiento farmacológico del trastorno por déficit de atención con hiperactividad. Med Clin (Barc) 2003; 120: 222-6
96. Stein MT, Perrin JM. Diagnosis and treatment of ADHD in school-age children in primary care settings: a sinopsis of the AAP practice guidelines. Pediatr Rev 2003; 24: 92-8
97. Dopfner M, Rothenberger A, Sonuga-Barke E. Areas for future investment in the field of ADHD: preschooler and clinical networks. Eur Child Adolesc Psychiatry 2004; 13 (Suppl 1): 130-5
98. Sergeant J. EUNETHYDIS -searching for valid aetiological candidates of attention-deficit hyperactivity disorder or hyperkinetic disorder. Eur Child Adolesc Psychiatry 2004; 13 (Suppl 1): 43-9
99. Rappley MD. Clinical practice. Attention deficit-hyperactivity disorder. N Engl J Med 2005; 352: 165-73
100. Biederman J, Faraone SV. Attention deficit-hyperactivity disorder. Lancet 2005; 366: 237-48
101. Lilienfeld SO. Scientifically unsupported and supported interventions for childhood psychopathology: a summary. Pediatrics 2005; 115: 761-4
102. Wolraich ML, Wibbelsman CJ, Brown TE, Evans SW, Gotlieb EM, Knight JR, et al. ADHD among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics 2005; 115: 1734-46.
103. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1073-86.
104. Wells KC, Pelham WE, Kotkin RA, Hoza B, Abikoff HB, Abramowitz A, et al. Psychosocial treatment strategies in the MTA study: rationale, methods, and critical issues in design and implementation. J Abnorm Child Psychol 2000; 28: 483-505.
105. Swanson JM, Arnold LE, Vitiello B, Abikoff HB, Wells KC, Pelham WE, et al. Response to commentary on the multimodal treatment study of ADHD (MTA): mining the meaning of the MTA. J Abnorm Child Psychol 2002; 30: 327-32.
106. The MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of Children with ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 2004; 113: 754-61.
107. The MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of Children with ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004; 113: 762-9.
108. Swanson J, Lerner M, March J, Gresham F. Assessment and intervention for ADHD in the schools: lessons from the MTA study. Pediatr Clin North Am 1999; 46: 993-1009.
109. Boyle MH, Jadad AR. Lessons from large trials: the MTA study as a model for evaluating treatment of childhood psychiatric disorder. Can J Psychiatry 1999; 44: 991-8.
110. Mulas F, Roselló B, Smeyers P, Hernández S. Trastorno por déficit de atención con hiperactividad: actualización diagnóstica y terapéutica. In: Actualidad en TDAH, 2. Madrid: Lab. Rubió/Jarpyo; 2002.
111. Cornellà Canals J, Llusent Guillamet A. Trastorno por déficit de atención con o sin hiperactividad. Ped Integral, 2003; 7: 571-82.
112. Carlson GA. Nuevas alternativas en el tratamiento farmacológico del TDAH. Jornada Internacional: el TDAH y su comorbilidad. Libro de ponencias. Barcelona; 2004.
113. Barsky AJ. The paradox of health. N Engl J Med 1988; 318: 414-8.
114. Muir Gray JA. Evidence-based healthcare. How to make health policy and management decisions. 2 ed. London: Churchill Livingstone; 2003.
115. González de Dios J. Búsqueda de información en Pediatría basada en la evidencia (I): 'infoxicación' e Internet. Rev Esp Pediatr 2003; 59: 246-58.
116. Guyatt GH, Sackett DL, Cook DJ. User's guide to the medical literature. II. How to use an article about therapy of prevention. A. Are the results of the study valid? JAMA 1993; 270: 2598-601.
117. Guyatt GH, Sackett DL, Cook DJ. User's guide to the medical literature. II. How to use an article about therapy of prevention. B. What were the results and will they help me in caring for my patients? JAMA 1994; 271: 59-63.
118. González de Dios J. Revisión crítica de publicaciones sobre tratamiento. Pediatr Integral 2002; 6: 455-62.
119. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jonrd J, et al. Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998; 155: 693-5.
120. Michelson D, Allen AJ, Busner J, Casat C, Duna D, Kratochvil C, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159: 1896-901.
121. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108: 83.
122. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002; 63: 1140-7.
123. Michelson D, Buitelaar JK, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004; 43: 896-904.
124. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, et al. Once-daily atomoxetine treatment for children with attention-deficit/ hyperactivity disorder, including an assessment of evening and morning behaviour: a double-blind, placebo-controlled trial. Pediatrics 2004; 114: 1-8.
125. Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 776-84.
126. Starr HL, Kemner J. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD. J Natl Med Assoc 2005; 97 (Suppl 12): S11-6.
127. Velásquez-Tirado JD, Peña JA. Evidencia actual sobre la atomoxetina. Alternativa terapéutica para el trastorno por déficit de atención e hiperactividad. Rev Neurol 2005; 41: 493-500.
128. Davidoff F, DeAngelis CD, Drazen JM, Nichols MG, Hoey J, Hojgaard L, et al. Sponsorship, authorship, and accountability. N Engl J Med 2001; 345: 825-7.
129. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002; 287: 612-7.
130. González de Dios J, Paredes C. Bioética, conflicto de intereses, industria farmacéutica y ensayos clínicos en Pediatría. An Pediatr (Barc) 2005; 62: 223-9.
131. Peiró S. Limitaciones y autolimitaciones de la medicina basada en la evidencia para la práctica clínica y la atención sanitaria. Med Clin (Barc) 2002; 118 (Supl 3): 49-56.
132. Soto J, Olivella P. ¿Son los medicamentos una inversión económicamente rentable para el sistema nacional de salud en España? Med Clin (Barc) 2001; 117: 622-4.
133. Peiró S. La construcción de la evidence b(i)ased medicine. Gestión Clínica y Sanitaria 2005; 7: 131-8. URL: http://www.iiss.es/gc/gestion26.pdf. Fecha última consulta: 15.01.2006.
134. Programa de lectura crítica CASPe. Entendiendo la evidencia sobre la eficacia clínica. 11 preguntas para dar sentido a un ensayo clínico. CASP española. URL: http://redcaspe.org/herramientas/ lectura/11ensayo.pdf. Fecha última consulta: 07.07.2005.